Development of prostate cancer and progression to androgen-independent disease is correlated with increased expression of growth factors and receptors capable of establishing autocrine and/or paracrine growth-stimulatory loops. A thorough review was made of the current literature and recent abstract presentations at scientific meetings focusing on the role of the HER-2/neu (c-erbB2) receptor in prostate cancer and the potential clinical usefulness of its specific inhibitors. In the past 10 years, conflicting results on HER-2/neu expression in prostate cancer have been reported. More recently, four studies have shown experimental evidence of HER-2/neu in the development of prostate cancer and, more specifically, in the progression to a hormone-refractory clinical behavior. Furthermore, it has been proposed that HER-2 family and androgen receptors function synergistically in the absence of androgen, which suggests a crosstalk between the HER-2/neu and androgen receptor pathways. Finally, clinical trials are in progress in prostate cancer patients to test novel agents that selectively interfere with HER-2/neu activity.
FeldmanB.J., FeldmanD.: The development of androgen independent prostate cancer.Nat Rev Cancer,1: 34–45, 2001.
4.
IsaacsW., De MarzoA., NelsonW.: Focus on prostate cancer.Cancer Cell,2: 113–116, 2002.
5.
EderI.E., CulingZ., PutzT.: Molecular biology of the androgen receptor from molecular understaining to the clinic.Eur Urol,40: 241–251, 2001.
6.
WareJ.L.: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer.Cancer Metastasis Rev,12: 287–301, 1993.
7.
SteinerM.S.: Role of peptide growth factors in the prostate: a review.Urology,42: 99–110, 1993.
8.
RussellP.F., BennettS., StrickerP.: Growth factor involvement in progression of prostate cancer.Clin Chem,44: 705–723, 1998.
9.
TillotsonJ.K., RoseD.P.: Density-dependent regulation of epidermal growth factor receptor expression in DU145 human prostate cancer cells.Prostate,19: 53–61, 1991.
10.
TraishA.M., WotizH.H.: Prostatic epidermal growth factor receptors and their regulation by androgens.Endocrinology,121: 1461–1467, 1987.
11.
HoferD.R., SherwoodE.R., BrombergW.D., MendelsohnJ., LeeC., KozlowskiJ.M.: The functional role of transforming growth factor α as an autocrine growth factor in androgen-in-dependent human prostatic carcinoma.Cancer Res,51: 2780–2785, 1991.
12.
SherH.I., SarkisA., ReuterV., CohenD., NettoG., PetrylakD., LianesP., FuksZ., MendelsohnJ., Cordon-CardoC.: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms.Clin Cancer Res,1: 545–550, 1995.
WoodburnJ.R.: The epidermal growth factor receptor and its inhibition in cancer therapy.Pharmacol Ther,82: 241–250, 1999.
20.
SungT., MillerD.C., HayesR.L., AlonsoM., YeeH., NewcombE.W.: Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade paediatric astrocytomas from de novo adult astrocytomas.Brain Pathol,10: 249–259, 2000.
21.
PorebskaI., HarlozinskaA., BojarowskiT.: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas.Tumor Biol,21: 105–115, 2000.
22.
SalomonD.S., BrandtR., CiardielloF., NormannoN.: Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol-Hematol,19: 183–232, 1995.
23.
NicholsonR.I., GeeJ.M.W., BarrowD., PammentJ.S., KnowldenJ.M., McClellandR.A.: Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Proc AACR-NCI-EORTC Meeting, Washington, DC, 1999.
24.
AkimotoT., HunterN.R., BuchmillerL., MasonK., AngK.K., MilasL.: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.Clin Cancer Res,5: 2884–2890, 1999.
25.
ChenZ., KeL.D., YuanX.H., Adler-StorthzK.: Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells.Anticancer Res,20: 899–902, 2000.
26.
SlamonD.J., ClarkG.M., WongS.G., LevinW.J., UllrichA., McGuireW.L.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,245: 177–182, 1987.
27.
SlamonD.J., GodolphinW., JonesL.A., HoltJ.A., WongS.G., KeithD.E., LevinW.J., StuartS.G., UdoveJ., UllrichA.: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer.Science,244: 707–712, 1989.
28.
NaberS.P., TsutsumiY., YinS., ZolnayS.A., MobtakerH., MarksP.J., McKenzieS.J., DeLellisR.A., WolfeH.J.: Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.Am J Clin Pathol,94: 125–136, 1990.
29.
BerchuckA., KamelA., WhitakerR., KernsB., OltG., KinneyR., SoperJ.T., DodgeR., Clarke-PearsonD L., MarksP.: Overexpression of Her-2/ neu is associated with poor survival in advanced epithelial ovarian cancer.Cancer Res,50: 4087–4091, 1990.
30.
De PlacidoS., CarlomagnoC., De LaurentiisM., BiancoA.R.: C-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.Breast Cancer Res Treat,52: 55–64, 1998.
31.
ShepardH.M., LewisG.D., SarupJ.C., FendlyB.M., ManevalD., MordentiJ., FigariI., KnottsC.E., PalladinoM.A.Jr., UllrichA.: Monoclonal antibody therapy of human cancer: taking the HER-2 protooncogene to the clinic.J Clin Immunol,11: 117–127, 1991.
32.
PegramM., HsuS., LewisG., PietrasR., BerytM., SliwkowskiM., CoombsD., BalyD., KabbinavarF., SlamonD.J.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene,18: 2241–2251, 1999.
33.
PegramM.D., SlamonD.: Combination therapy with trastuzumab (Herceptin) for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.Semin Oncol,26(suppl. 12): 89–95, 1999.
34.
Abate-ShenC., ShenM.M.: Molecular genetics of prostate cancer.Genes Dev,14: 2410–2434, 2000.
35.
di Sant'AgneseP.A.: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications.Cancer,70: 254–268, 1992.
36.
AbrahamssonP.A.: Neuroendocrine differentiation in prostatic carcinoma.Prostate,39: 135–148, 1999.
37.
KokontisJ.M., LiaoS.: Molecular action of androgen in the normal and neoplastic prostate.Vitam Horm,55: 219–307, 1999.
38.
McKeehanW.L., AdamsP.S., RosserM.P.: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin but not androgen on normal rat prostate epithelial cells in serum free primary cell culture.Cancer Res,4: 1998–2010, 1984.
39.
ByrneR.L., LeungH., NealD.E.: Peptide growth factors in the prostate as mediators of stromal epithelial interaction.Br J Urol,77: 627–633, 1996.
40.
JensterG.: The role of androgen receptor in the development and progression of prostate cancer.Semin Oncol,26: 407–421, 1999.
41.
RussellP.J., BennettS., StrickerP.: Growth factor involvement in progression of prostate cancer.Clin Chem,44: 705–723, 1998.
42.
MellonK., ThompsonS., CharltonR.G., MarshC., RobinsonM., LaneD.P., HarrisA.L., Wilson HorneC.H., NealD.E.: P53, c-erbB2 and the epidermal growth factor receptor in the benign and malignant prostate.J Urol,147: 496–499, 1992.
43.
GiriD.K., WadhwaN., UpadhayaS.N., TalwarG.P.: Expression of Neu/HER-2 oncoprotein in prostate tumors: an immunohistochemical study.Prostate,23: 329–336, 1993.
44.
SadasivanR., MorganR., JenningsS., AustenfeldM., Van VeldhizenP., StephensR., NobleM.: Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer.J Urol,150: 126–131, 1993.
45.
GiriD.K., PalR., WadhwaS.N., TalwarG.P.: Immunohistochemical localization of transforming growth factor alpha, epidermal growth factor receptor and c-erbB2 protein in hyperplastic human prostates.Carcinogenesis,16: 729–733, 1995.
46.
SchwartzS.Jr., CaceresC., MoroteJ., De TorresI., Rodriguez-ValleioJ.M., GonzalezJ., ReventosJ.: Overexpression of epidermal growth factor receptor and c-erbB2/neu but not int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR.Cancer,5: 197–204, 2002.
47.
WatanabeM., NakadaT., YutaH.: Analysis of protooncogene c-erbB2 in benign and malignant human prostate.Int Urol Nephrol,31: 61–73, 1999.
48.
WareJ.L., MaygardenS.J., KoontzW.W., StromS.C.: Immunohistochemical detection of c-erbB2 protein in human benign and neoplastic prostate.Hum Pathol,22: 254–258, 1991.
49.
VisakorpiT., KalloniemiO.P., KoivulaT., HarveyJ., IsolaJ.: Expression of epidermal growth factor receptor and ERBB2 (HER-2/NEU) oncoprotein in prostatic carcinomas.Mod Pathol,5: 643–648, 1992.
50.
KuhnE.J., KurnotR.A., SesterhennI.A., ChangE.H., MoulJ.W.: Expression of the c-erbB2 (her-2/neu) oncoprotein in human prostatic carcinoma.J Urol,150: 1427–1433, 1993.
51.
RossJ.S., NazeerT., ChurchK., AmatoC., FiggeH., RifkinM.D.: Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma and metastasis.Cancer,72: 3020–3028, 1993.
52.
VeltriR.W., PartinA.W., EpsteinJ.E., MarleyG.M., MillerC.M., SingerD.S.: Quantitative nuclear morphometry, Markovian texture descriptors and DNA content captured on CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.J Cell Biochem,19: 249–258, 1994.
53.
GuK., Mes-MassonA.M., GauthierJ., SaadF.: Overexpression of the her-2/neu in human prostate cancer and benign hyperplasia.Cancer Lett,99: 185–189, 1996.
54.
RossJ.S., SheehanC.E., Hayner-BuchanA.M., AmbrosR.A., KallakuryB.V., KaufmanR.P.Jr., FisherH.A., RifkinM.D., MuracaP.J.: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.Cancer,79: 2162–2170, 1997.
55.
FoxS.B., PersadR.A., ColemanN., DayC.A., SilcocksP.B., CollinsC.C.: Prognostic value of c-erbB2 and EGFR in stage A1 (T1a) prostatic adenocarcinoma.Br J Urol,74: 214–220, 1994.
56.
MyersR.B., SrivastavaS., OelschlagerD.K., GrizzleW.E.: Expression of p160erbB-3 and p185erbB2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.J Natl Cancer Inst,86: 1140–1145, 1994.
57.
FossaA., LillebyW., FossaS.D., GaudernackG., TorlakovicG., BernerA.: Independent prognostic significance of HER-2 oncoprotein expression in pNo prostate cancer undergoing curative radiotherapy.Int J Cancer,99: 100–105, 2002.
58.
JordaM., MoralesA., GhorabZ., FernandezG., NadjiM., BlockN.: Her-2 expression in prostatic cancer: a comparison with mammary carcinoma.J Urol,168: 1412–1414, 2002.
59.
LaraP.M., MeyersF.J., EdwardsR.G., GumerlockP.H., KaundererC., TichauerG., TwardowskiP., DoroshowJ.H., GandaraD.R.: Her-2/NEU is overexpressed infrequently in patients with prostate carcinoma.Cancer,94: 2584–259, 2002.
60.
SanchezK.M., SweeneyC.J., MassR., KochM.O., GearyW.A., BaldridgeL.A., ZhangS., EbleJ.N., ChengL.: Evaluation of HER-2/neu expression in prostatic adenocarcinoma.Cancer,95: 1650–1655, 2002.
61.
RossJ.S., SheehanC.E., Hayner-BuchanA.M., AmbrosR.A., KallakuryB.V., KaufmanR.: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridisation.Hum Pathol,28: 827–33, 1997.
62.
KallakuryB.V., SheehanC.E., AmbrosR.A., FisherH.A., KaufmanR.P.Jr., MuracaPl: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarinomas.J Clin Oncol,16: 1302–1309, 1998.
63.
BubendorfL., KononenJ., KoivistoP., SchramlP., MochH., GasserT.C., WilliN., MihatschM.J., SauterG., KallioniemiO.P.: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.Cancer Res,59: 803–806, 1999.
64.
MarkH.F., FeldmanD., DasS., SamyM., SunC.L., MarkS.: Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.Exp Mol Pathol,66: 170–178, 1999.
65.
SchwartzS.Jr., CaceresC., MoroteJ., De TorresI., Rodriguez-VallejoJ.M., GonzalezJ., ReventosJ.: Gains of the relative genomic content of erbB 1 and erbB2 in prostate carcinoma and their correlation with metastasis.Int J Oncol14: 267–2711999.
66.
SignorettiS., MontironiR., ManolaJ., AltimariA., TamC., BubleyG., BalkS., ThomasG., KaplanI., HlatkyL., HahnfeldtP., KantoffP., LodaM.: Her-2-neu expression and progression toward androgen independence in human prostate cancer.J Natl Cancer Inst,92: 1918–1925, 2000.
67.
OsmanI., SherH.I., DrobnjakM., VerbelD., MorrisM., AgusD., RossJ.S., Cordon-CardoC.: Her-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.Clin Cancer Res,7: 2643–2647, 2001.
68.
ShyY., BrandsF.H., ChatterjeeS., FengA.C., GroshenS., ScheweJ., LieskovskyG., CoteR.J.: Her-2/NEU expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.J Urol,166: 1514–1519, 2001.
69.
Di LorenzoG., TortoraG., D'ArmientoF., De RosaG., StaibanoS., AutorinoR., D'ArmientoM., De LaurentiisM., De PlacidoS., CatalanoG., BiancoA.R., CiardielloF.: Expression of epidermal growth factor (EGFR) correlates with disease relapse and progression to androgen-independence in human prostate cancer.Clin Cancer Res,8: 3438–3444, 2002.
70.
CraftN., ShostakY., CareyM., SawyersC.L.: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase.Nat Med,5: 280–285, 1999.
Magi-GalluzziC., MishraR., FiorentinoM., MontironiR., YaoH., CapodieciP., WishnowK., KaplanI., StorkP.J., LodaM.: Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancer and is inversely related to apoptosis.Lab Invest,76: 37–51, 1997.
73.
GioeliD., MandellJ.W., PetroniG.R., FriersonH.F.Jr., WeberM.J.: Activation of mitogen-activated protein kinase associated with prostate cancer progression.Cancer Res,59: 279–284, 1999.
74.
YehS., Kuan-LinH., KangH.Y., ThinT.H., Fong LinM., ChangC.: From HER-2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.Proc Natl Acad Sci,96: 5458–5463, 1999.
75.
LeeY.F., LinW.J., HuangJ., MessingE.M., ChanF.L., WildingG., ChangC.: Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.Cancer Res,62: 6039–6044, 2002.
76.
YaoR., CooperG.M.: Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity.Oncogene,13: 343–351, 1996.
77.
ParrizasM., SaltielA.R., LeRothD.: Insulin-like growth factor-1 inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen activated protein kinase pathways.J Biol Chem,272: 154–161, 1997.
78.
CrowderR.J., FreemanR.S.: Phosphatidylinositol 3-kinase and AKT protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons.J Neurosci,18: 2933–2943, 1998.
79.
WhitmanM.C., DownesP., KeelerM., KellerT., CantleyL.: Type I phosphatidylinositol 3-kinase makes a novel inositol phospholipid, phosphatidylinositol-3 phosphate.Nature,332: 644–646, 1998.
80.
Del PesoL., Gonzalez-GarciaM., PageC., HerreraR., NunezG.: Interleukin-3 induced phosphorylation of BAD through the protein kinase AKT.Science,278: 687–689, 1997.
81.
LinJ., AdamR.M., SantiestevanE., FreemanM.R.: The phosphatidylinositol 3’ kinase is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.Cancer Res,59: 2891–2897, 1999.
82.
SharmaM., ChuangW.W., SunZ.: Phosphatidylinositol 3’ kinase/AKT stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation.J Biol Chem,277: 30935–30941, 2002.
83.
TyagiA., AgarwalR., AgarwalC.: Grape seed extract inhibits EGF-induced and constitutively active mitogenic signalling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.Oncogene,22: 1302–1316, 2003.
KueP.F., TaubJ., Barki-HarringtonL.: Lisophosphatidic acid regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC3 cells.Int J Cancer,102: 572–579, 2003.
86.
YeR.D.: Regulation of nuclear factor Kb activation by G protein-coupled receptors.J Leuk Biol,70: 839–848, 2001.
87.
RajG.V., Barki-HarringtonI., KueP.F., DaakaY.: Guanosine phosphate binding protein coupled receptors in prostate cancer.J Urol,167: 1458–1463, 2002.
88.
KarinM.: The beginning of the end: IkB kinase (IKK) and NF-Kb activation.J Biol Chem,274: 27339–27342, 1999.
89.
SmallE.J., BokR., ReeseD.M., SudilovskyD., FrohlichM.: docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.Semin Oncol,4(suppl. 15): 71–76, 2001.
90.
MorrisM.J., ReuterV.E., KellyW.K., SlovinS.F., KennesonK., VerbelD., OsmanI., ScherH.I.: HER-2 profiling and targeting in prostate carcinoma.Cancer,94: 980–986, 2002.
91.
SirotnakF.M., SheY., LeeF., SherH.I.: Studies with CWR22 xenograft models in nude mice suggest that ZD1839 (Iressa) may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.Proc Am Assoc Cancer Res,42: A542, 2001.
92.
MillerK., RaabeN., TrachtenbergJ., TrumpD., WildingG., Das-GuptaA.: ZD1839, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKi) is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC).Ann Oncol,13(suppl. 5) (abst 3270), ESMO Congress, 2002.
93.
SoulièP., TrumpD., WildingG., SmallE., Das-GuptaA.: ZD1839, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKi) in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC).Ann Oncol, 13 (Suppl 5), 3280 (abst), ESMO Congress, 2002.
94.
NormannoN., CampiglioM., De LucaA., SomenziG., MaielloM., CiardielloF., GianniL., SalomonD.S., MenardS.: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.Ann Oncol,13: 65–72, 2002.
95.
MoulderS.L., YakesF.M., BiancoR., ArteagaC.L.: A rationale for the use of small molecule EGF receptor tyrosine kinase inhibitors against HER2/neu (erbB2) overexpressing breast tumor cells.Proc Am Assoc Cancer Res,42: A4573, 2001.
96.
AnidoJ., AlbanellJ., RojoF., Codony-ServatJ., ArribasJ., BaselgaJ.: Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells.Proc ASCO,21: 1712A, 2001.
